June 3, 2020 / 12:09 PM / a month ago

BRIEF-Replimune Provides RP1 Data Update From Phase 2 Cohorts In Melanoma And Non-Melanoma Skin Cancer

June 3 (Reuters) - Replimune Group Inc:

* REPLIMUNE PROVIDES RP1 DATA UPDATE FROM ITS PHASE 2 COHORTS IN MELANOMA AND NON-MELANOMA SKIN CANCER THAT STRONGLY SUPPORT REPLIMUNE’S ONGOING REGISTRATION-DIRECTED CLINICAL TRIALS WITH RP1

* REPLIMUNE GROUP - HIGH RATE OF DEEP RESPONSES IN ANTI-PD-1 / ANTI-CTLA-4 REFRACTORY MELANOMA

* REPLIMUNE GROUP - INTENTION TO COMMENCE CLINICAL DEVELOPMENT IN ANTI-PD-1 REFRACTORY NON-SMALL CELL LUNG CANCER

* REPLIMUNE GROUP - MULTIPLE COMPLETE RESPONSES OBSERVED IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

* REPLIMUNE GROUP - DATA CONTINUES TO DEMONSTRATE THAT RP1 IN COMBINATION WITH OPDIVO IS WELL-TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below